Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents

Prostate cancer (PCa) is a clinically heterogeneous disease with a progressively increasing incidence. Concurrent inhibition of coactivator-associated arginine methyltransferase 1 (CARM1) and histone deacetylase 2 (HDAC2) could potentially be a novel strategy against PCa. Herein, we identified seven...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Sudong, Geng, Yifei, Niu, Miao-Miao, Zhang, Yan, He, Weiping, Li, Jindong, Yang, Li, Xu, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399481/
https://www.ncbi.nlm.nih.gov/pubmed/37528657
http://dx.doi.org/10.1080/14756366.2023.2241118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399481/
https://www.ncbi.nlm.nih.gov/pubmed/37528657
http://dx.doi.org/10.1080/14756366.2023.2241118

Ejemplares similares